Cargando...
Targeted Degradation of Oncogenic KRAS(G12C) by VHL-Recruiting PROTACs
[Image: see text] KRAS is mutated in ∼20% of human cancers and is one of the most sought-after targets for pharmacological modulation, despite having historically been considered “undruggable.” The discovery of potent covalent inhibitors of the KRAS(G12C) mutant in recent years has sparked a new wav...
Gardado en:
| Publicado en: | ACS Cent Sci |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Chemical Society
2020
|
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7453568/ https://ncbi.nlm.nih.gov/pubmed/32875077 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acscentsci.0c00411 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|